Aurgalys Team
Selected Customers
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]

June 8th, 2015: Performance of French Life Sciences and Healthcare Smallcaps: total market capitalization of €10.2B

juin 08, 2015

Paris-Evry, France, June 8th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued its monthly publication of its indices measuring the performance of French, Life Sciences and Healthcare smallcaps.

With a 6.4% increase in May 2015, the French Biotech/Medtech Smallcaps reached a total market capitalization of €10.2 B. Out of the 57 companies included in the Alys France index, 27 are listed in Alternext Paris. As a comparison, Alternext alone weighs €10 B. Again, the Alys Therapeutics showed the strongest performance with a 10.1% increase. This is mainly explained by Cellectis’s 37.1% increase in May, following rumors of a potential acquisition by Pfizer.

You can download our report on the following link:

Comments are closed.